Eirion Overview
- Founded
- 2016
- Status
- Private
- Latest Deal Type
- Series A
- Latest Deal Amount
- $43M
- Investors
- 4
Eirion General Information
Description
Developer of prescription products intended for aesthetic dermatology. The company's products focus on the treatment of wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying, thereby enabling patients to get rid of problems like lateral canthal lines.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- 25-K Olympia Avenue
- Suite 200
- Woburn, MA 01801-6399
- United States
+1 (781) 000-0000
Eirion Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC (Series A) | 09-Mar-2021 | $43M | 0000 | Completed | Clinical Trials - Phase 2 | |
| 1. Spin-Off | 01-Jan-2016 | Completed | Startup |
Eirion Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jon Edelson MD | Chief Executive Officer, Chairman & President | ||
| Klaus Theobald Ph.D | Chief Research & Development Officer |
Eirion Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barry Kurokawa | Self | Board Member | 000 0000 |
| Jon Edelson MD | Eirion | Chief Executive Officer, Chairman & President | 000 0000 |
Eirion Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Shanghai Hao Hai Healthcare | Corporation | Minority | 000 0000 | 000000 0 | |
| Praesideo Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Scientific Health Development | Venture Capital | Minority | 000 0000 | 000000 0 | |
| The Spring Bay Companies | Venture Capital | Minority | 000 0000 | 000000 0 |